...
search icon
clrb-img

Cellectar Biosciences Inc Share Price

CLRB
NAQ
$3.175
-$0.12
(-3.65%)
1D
Industry: Biotechnology Sector: Health Care

Cellectar Biosciences Inc Analyst Forecast

Cellectar Biosciences Inc Share Price Chart

Cellectar Biosciences Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$13.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
23.35K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.31
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.45 L
$20.59 H
$3.175

About Cellectar Biosciences Inc, Common Stock

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. more

Industry: BiotechnologySector: Health Care

Cellectar Biosciences Inc Stock Returns

Time FrameCLRBSectorS&P500
1-Week Return8.22%-0.03%-1.31%
1-Month Return-18.56%0.59%-1.75%
3-Month Return14.63%3.23%1.44%
6-Month Return-25.57%18.29%5.74%
1-Year Return-60.97%7.71%11.81%
3-Year Return-93.62%18.03%65.25%
5-Year Return-99.54%35.78%73.79%
10-Year Return-99.98%140.42%260.26%

Cellectar Biosciences Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue207.93K227.64K238.87K192.38K291.65K[{"date":"2020-12-31","value":71.29,"profit":true},{"date":"2021-12-31","value":78.05,"profit":true},{"date":"2022-12-31","value":81.9,"profit":true},{"date":"2023-12-31","value":65.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(207.93K)(227.64K)(238.87K)(192.38K)(291.65K)[{"date":"2020-12-31","value":-20792900,"profit":false},{"date":"2021-12-31","value":-22763600,"profit":false},{"date":"2022-12-31","value":-23886700,"profit":false},{"date":"2023-12-31","value":-19237500,"profit":false},{"date":"2024-12-31","value":-29165300,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses15.29M24.13M28.81M38.96M51.78M[{"date":"2020-12-31","value":29.53,"profit":true},{"date":"2021-12-31","value":46.61,"profit":true},{"date":"2022-12-31","value":55.65,"profit":true},{"date":"2023-12-31","value":75.25,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(15.29M)(24.13M)(28.81M)(38.96M)(51.78M)[{"date":"2020-12-31","value":-1529034900,"profit":false},{"date":"2021-12-31","value":-2413128000,"profit":false},{"date":"2022-12-31","value":-2881377300,"profit":false},{"date":"2023-12-31","value":-3896064300,"profit":false},{"date":"2024-12-31","value":-5177769800,"profit":false}]
Total Non-Operating Income/Expense207.07K11.20K305.04K(3.47M)8.47M[{"date":"2020-12-31","value":2.44,"profit":true},{"date":"2021-12-31","value":0.13,"profit":true},{"date":"2022-12-31","value":3.6,"profit":true},{"date":"2023-12-31","value":-41.01,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(15.09M)(24.12M)(28.66M)(42.83M)(44.52M)[{"date":"2020-12-31","value":-1509417200,"profit":false},{"date":"2021-12-31","value":-2412236200,"profit":false},{"date":"2022-12-31","value":-2866125400,"profit":false},{"date":"2023-12-31","value":-4283061000,"profit":false},{"date":"2024-12-31","value":-4451544600,"profit":false}]
Income Taxes(337.63K)(152.20K)(60.00K)(60.00K)66.00K[{"date":"2020-12-31","value":-511.56,"profit":false},{"date":"2021-12-31","value":-230.6,"profit":false},{"date":"2022-12-31","value":-90.91,"profit":false},{"date":"2023-12-31","value":-90.91,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(14.76M)(23.97M)(28.60M)(42.77M)(44.58M)[{"date":"2020-12-31","value":-1475654200,"profit":false},{"date":"2021-12-31","value":-2397016300,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-4277061000,"profit":false},{"date":"2024-12-31","value":-4458144600,"profit":false}]
Income From Continuous Operations(15.09M)(24.12M)(28.60M)(37.75M)(44.58M)[{"date":"2020-12-31","value":-1509417200,"profit":false},{"date":"2021-12-31","value":-2412236200,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-3774993100,"profit":false},{"date":"2024-12-31","value":-4458144600,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(15.09M)(23.97M)(28.60M)(42.77M)(44.58M)[{"date":"2020-12-31","value":-1509417200,"profit":false},{"date":"2021-12-31","value":-2397016300,"profit":false},{"date":"2022-12-31","value":-2860125400,"profit":false},{"date":"2023-12-31","value":-4277061000,"profit":false},{"date":"2024-12-31","value":-4458144600,"profit":false}]
EPS (Diluted)(9.00)(4.30)(4.05)(2.93)(1.44)[{"date":"2020-12-31","value":-900,"profit":false},{"date":"2021-12-31","value":-430,"profit":false},{"date":"2022-12-31","value":-405,"profit":false},{"date":"2023-12-31","value":-293,"profit":false},{"date":"2024-12-31","value":-144,"profit":false}]

Cellectar Biosciences Inc Ratios

Cellectar Biosciences Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CLRB
Cash Ratio 2.56
Current Ratio 2.77

Cellectar Biosciences Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CLRB
ROA (LTM) -72.31%
ROE (LTM) -145.42%

Cellectar Biosciences Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CLRB
Debt Ratio Lower is generally better. Negative is bad. 0.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.64

Cellectar Biosciences Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CLRB
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.87
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Cellectar Biosciences Inc share price today?

Cellectar Biosciences Inc (CLRB) share price today is $3.175

Can Indians buy Cellectar Biosciences Inc shares?

Yes, Indians can buy shares of Cellectar Biosciences Inc (CLRB) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLRB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cellectar Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Cellectar Biosciences Inc (CLRB) via the Vested app. You can start investing in Cellectar Biosciences Inc (CLRB) with a minimum investment of $1.

How to invest in Cellectar Biosciences Inc shares from India?

You can invest in shares of Cellectar Biosciences Inc (CLRB) via Vested in three simple steps:

  • Click on Sign Up or Invest in CLRB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cellectar Biosciences Inc shares
What is Cellectar Biosciences Inc 52-week high and low stock price?

The 52-week high price of Cellectar Biosciences Inc (CLRB) is $20.59. The 52-week low price of Cellectar Biosciences Inc (CLRB) is $2.45.

What is Cellectar Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cellectar Biosciences Inc (CLRB) is

What is Cellectar Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cellectar Biosciences Inc (CLRB) is 1.87

What is Cellectar Biosciences Inc dividend yield?

The dividend yield of Cellectar Biosciences Inc (CLRB) is 0.00%

What is the Market Cap of Cellectar Biosciences Inc?

The market capitalization of Cellectar Biosciences Inc (CLRB) is $13.95M

What is Cellectar Biosciences Inc's stock symbol?

The stock symbol (or ticker) of Cellectar Biosciences Inc is CLRB

How Can Investors Use Cellectar Biosciences Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Cellectar Biosciences Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cellectar Biosciences Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Cellectar Biosciences Inc shares for Indian investors?

When investing in Cellectar Biosciences Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cellectar Biosciences Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Cellectar Biosciences Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Cellectar Biosciences Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cellectar Biosciences Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top